ObjectiveTo observe the clinical efficacy of chemotherapy combined with DC-CIK cell immunotherapy in treatment of elderly patients with cardia cancer. MethodsA total of 64 elderly patients with cardia cancer were randomly divided into research group (n=34) and control group (n=30), the control group received chemotherapy, and the research group was treated with DC-CIK cell immunotherapy on the basis of chemotherapy. A month after the treatment, the clinical efficacy, quality of life and adverse reactions were compared between two groups, and the evaluation criteria in tumors set by WHO was used to evaluated the clinical efficacy. ResultsThe clinical efficacy and quality of life in the research group were significantly superior to those in the control group (P＜0.05); the incidence rate of adverse reactions in the research group was significantly lower than that in the control group (P＜0.05). ConclusionsDC-CIK cell immunotherapy in adjuvant therapy of elderly cardia cancer can improve the curative effect, which is worth popularizing in clinical practice.

无